Stocks › MDGL

MADRIGAL PHARMACEUTICALS, INC.

MDGL·Nasdaq·United States United States·USD
$379.10
-17.64 (-4.45%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
MDGL
MADRIGAL PHARMACEUTICALS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
MDGLS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of MDGL by members of U.S. Congress · 1 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Daniel S. GoldmanDaniel S. GoldmanHouse · D · NY MDGLMADRIGAL PHARMACEUTICALS, INC. · Stock Sale
$1,001 - $15,000
May 19, 2023 Apr 10, 2023 Filing ↗

Whale Activity

Position changes in MDGL reported for 2026-09-30 by 491 institutional filers
Increased: 156New: 77Held: 62Decreased: 126Closed: 49No prior filing: 21
  • Increased156
  • New77
  • Held62
  • Decreased126
  • Closed49
  • No prior filing21
FilerSharesValueChange
BAKER BROS. ADVISORS LP2.1M$1.08Bheld
Janus Henderson Group Ltd.2.0M$993.9M—
Avoro Capital Advisors LLC1.8M$923.9Mheld
PAULSON & CO. INC.1.5M$751.7Mincreased
BlackRock, Inc.1.2M$624.4Mincreased
WELLINGTON MANAGEMENT GROUP LLP928.8K$468.1Mincreased
VANGUARD CAPITAL MANAGEMENT LLC846.6K$426.7Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC761.0K$383.5Mdecreased
AQR CAPITAL MANAGEMENT LLC636.2K$320.6Mincreased
STATE STREET CORP595.8K$300.2Mincreased
AMERIPRISE FINANCIAL INC448.4K$226.0M—
GEODE CAPITAL MANAGEMENT, LLC368.8K$185.9Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by MDGL insiders, by quarter · Form 4
-200.0K-100.0K0100.0K200.0K2025 Q1: -75.8K2025 Q12025 Q2: 02025 Q22025 Q3: -143.3K2025 Q32025 Q4: -77.1K2025 Q42026 Q1: -55.6K2026 Q12026 Q2: -7,5682026 Q22026 Q3: -14.7K2026 Q32026 Q4: 90.7K2026 Q4

Recent Insider Transactions

961 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Kelley Shannon TGeneral Counsel Sale −1,077 $400.00 $431K Nov 6, 2026 Form 4 ↗
BAKER BROS. ADVISORS LP / Baker Bros. Advisors (GP) LLC / BAKER FELIX / BAKER JULIAN / 667, L.P. / Baker Brothers Life Sciences LPDirector · Director Purchase +60.4K $383.01 $23.1M Nov 6, 2026 Form 4 ↗
BAKER BROS. ADVISORS LP / Baker Bros. Advisors (GP) LLC / BAKER FELIX / BAKER JULIAN / 667, L.P. / Baker Brothers Life Sciences LPDirector · Director Purchase +2,000 $396.61 $793K Nov 6, 2026 Form 4 ↗
BAKER BROS. ADVISORS LP / Baker Bros. Advisors (GP) LLC / BAKER FELIX / BAKER JULIAN / 667, L.P. / Baker Brothers Life Sciences LPDirector · Director Purchase +13.7K $388.29 $5.3M Nov 6, 2026 Form 4 ↗
BAKER BROS. ADVISORS LP / Baker Bros. Advisors (GP) LLC / BAKER FELIX / BAKER JULIAN / 667, L.P. / Baker Brothers Life Sciences LPDirector · Director Purchase +5,586 $366.99 $2.1M Nov 4, 2026 Form 4 ↗
BAKER BROS. ADVISORS LP / Baker Bros. Advisors (GP) LLC / BAKER FELIX / BAKER JULIAN / 667, L.P. / Baker Brothers Life Sciences LPDirector · Director Purchase +10.1K $368.11 $3.7M Nov 4, 2026 Form 4 ↗
Sibold William JohnPresident and CEO · Director Sale −120 $546.38 $66K Sep 11, 2026 Form 4 ↗
Sibold William JohnPresident and CEO · Director Sale −761 $544.83 $415K Sep 11, 2026 Form 4 ↗
Sibold William JohnPresident and CEO · Director Sale −1,539 $544.02 $837K Sep 11, 2026 Form 4 ↗
Sibold William JohnPresident and CEO · Director Sale −1,202 $542.60 $652K Sep 11, 2026 Form 4 ↗
Sibold William JohnPresident and CEO · Director Sale −368 $541.64 $199K Sep 11, 2026 Form 4 ↗
Sibold William JohnPresident and CEO · Director Sale −687 $540.59 $371K Sep 11, 2026 Form 4 ↗
Sibold William JohnPresident and CEO · Director Sale −160 $537.62 $86K Sep 11, 2026 Form 4 ↗
Sibold William JohnPresident and CEO · Director Sale −218 $535.94 $117K Sep 11, 2026 Form 4 ↗
Sibold William JohnPresident and CEO · Director Sale −106 $534.06 $57K Sep 11, 2026 Form 4 ↗
Sibold William JohnPresident and CEO · Director Sale −60 $533.09 $32K Sep 11, 2026 Form 4 ↗
Sibold William JohnPresident and CEO · Director Sale −160 $542.55 $87K Sep 9, 2026 Form 4 ↗
Sibold William JohnPresident and CEO · Director Sale −362 $541.65 $196K Sep 9, 2026 Form 4 ↗
Sibold William JohnPresident and CEO · Director Sale −505 $540.19 $273K Sep 9, 2026 Form 4 ↗
Sibold William JohnPresident and CEO · Director Sale −215 $539.03 $116K Sep 9, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding MDGL · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
585.0K$314.1M0.01%Jun 30, 2026
VANGUARD HEALTH CARE FUND
VANGUARD SPECIALIZED FUNDS
563.1K$263.2M0.69%Jul 31, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
423.1K$227.2M0.12%Jun 30, 2026
Janus Henderson Forty Fund
Janus Investment Fund
338.6K$181.8M0.76%Jun 30, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
243.7K$130.8M0.28%Jun 30, 2026
Janus Henderson Enterprise Fund
Janus Investment Fund
233.3K$125.3M0.56%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
216.9K$116.5M0.12%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
211.3K$113.4M1.06%Jun 30, 2026
Janus Henderson Contrarian Fund
Janus Investment Fund
168.3K$90.3M1.65%Jun 30, 2026
VANGUARD EXPLORER FUND190.1K$88.9M0.40%Jul 31, 2026

Mutual funds and ETFs whose N-PORT filings list MDGL's shares (CUSIP 558868105), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Roderick WongSCHEDULE 13G/A · passive (13G) · 312.8K shares1.4%
    Nov 16, 2026 · ↗
  • RTW Investments, LPSCHEDULE 13G/A · passive (13G) · 312.8K shares1.4%
    Nov 16, 2026 · ↗
  • Felix J. BakerSCHEDULE 13D/A · activist (13D) · 2.3M shares10.0%
    Nov 6, 2026 · ↗
  • Julian C. BakerSCHEDULE 13D/A · activist (13D) · 2.3M shares10.0%
    Nov 6, 2026 · ↗
  • Baker Bros. Advisors (GP) LLCSCHEDULE 13D/A · activist (13D) · 2.3M shares10.0%
    Nov 6, 2026 · ↗
  • Baker Bros. Advisors LPSCHEDULE 13D/A · activist (13D) · 2.3M shares10.0%
    Nov 6, 2026 · ↗
  • BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 1.1M shares4.6%
    Jul 29, 2026 · ↗
  • JANUS HENDERSON GROUP PLCSCHEDULE 13G/A · passive (13G) · 2.0M shares8.8%
    May 15, 2026 · ↗
  • PAULSON & CO. INC.SCHEDULE 13G/A · passive (13G) · 1.4M shares6.1%
    May 15, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming madrigal pharmaceuticals as client
$0$500K$1.0M$1.5M$2.0M2024 Q4: $60K20242025 Q1: $60K2025 Q2: $60K2025 Q3: $110K2025 Q4: $510K20252026 Q1: $610K2026 Q2: $610K2026 Q3: $580K2026
  • CAPITOL COUNSEL LLCMADRIGAL PHARMACEUTICALS, INC. · 2026 Q3 · HCR, MED, MMM$60K
    Filing ↗
  • MADRIGAL PHARMACEUTICALS, INC.MADRIGAL PHARMACEUTICALS, INC. · 2026 Q3 · MMM, HCR$350K
    Filing ↗
  • CROSSROADS STRATEGIES, LLCMADRIGAL PHARMACEUTICALS, INC. · 2026 Q3 · HCR, MMM$50K
    Filing ↗
  • BALLARD PARTNERS, LLCMADRIGAL PHARMACEUTICALS, INC. · 2026 Q3 · PHA$120K
    Filing ↗
  • MADRIGAL PHARMACEUTICALS, INC.MADRIGAL PHARMACEUTICALS, INC. · 2026 Q2 · MMM, HCR$380K
    Filing ↗

Government Contracts

Federal awards to madrigal pharmaceuticals · USAspending
$30KAwarded · 1 contract on record
  • Department of Veterans AffairsREZDIFFRA 80 MG$30K
    Jun 5, 2026 · ↗

U.S. Patents

Recent USPTO applications naming MADRIGAL PHARMACEUTICALS, INC.

No USPTO patent applications found for MADRIGAL PHARMACEUTICALS, INC..

Annual Financials

From MDGL's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$958.4M$180.1M$0$0$0
Operating income-$300.1M-$497.9M-$380.5M-$293.6M-$242.5M
Net income-$288.3M-$465.9M-$373.6M-$295.4M-$241.8M
Diluted EPS-$12.85-$21.90-$19.99-$17.23-$14.63
Operating cash flow-$189.6M-$455.6M-$324.2M-$224.9M-$183.9M
Cash and equivalents$198.7M$100.0M$99.9M$331.5M$36.3M
Total assets$1.26B$1.04B$640.5M$362.6M$273.3M
Total liabilities$656.9M$287.9M$235.2M$165.2M$77.2M
Shareholders' equity$602.7M$754.4M$405.3M$197.4M$196.1M

As MADRIGAL PHARMACEUTICALS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 19, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-35Reverse splitJul 25, 2016

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 3, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureAug 12, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsJul 30, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 17, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 6, 2026
    EDGAR ↗

About MADRIGAL PHARMACEUTICALS, INC.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersWEST CONSHOHOCKEN, PA
IncorporatedDE
Former namesMADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP